CBER’s New Director “Marks” A New Era For Biologics Regulation
This article was originally published in RPM Report
Executive Summary
Peter Marks takes over the top spot in the center for biologics at FDA after a four year training period as deputy director. His background appears well suited to what promises to be a transformative era in medicine.
You may also be interested in...
FDA's Califf Seeks His First Big Hire: Chief Scientist
The US agency seeks candidates for the executive position in charge of its research policy apparatus.
FDA Chief Scientist Post A Chance For Califf To Make Mark
Agency seeks candidates for the executive position in charge of its research policy apparatus.
The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.